Search results for "HCCS"

showing 10 items of 20 documents

Dynamics and predicted drug response of a gene network linking dedifferentiation with β-catenin dysfunction in hepatocellular carcinoma

2019

Background & Aims Alterations of individual genes variably affect the development of hepatocellular carcinoma (HCC). Thus, we aimed to characterize the function of tumor-promoting genes in the context of gene regulatory networks (GRNs). Methods Using data from The Cancer Genome Atlas, from the LIRI-JP (Liver Cancer – RIKEN, JP project), and from our transcriptomic, transfection and mouse transgenic experiments, we identify a GRN which functionally links LIN28B-dependent dedifferentiation with dysfunction of β-catenin (CTNNB1). We further generated and validated a quantitative mathematical model of the GRN using human cell lines and in vivo expression data. Results We found that LIN28B and C…

0301 basic medicineBeta-cateninCarcinoma HepatocellularHepatocellular carcinomaLIN28BCellGene regulatory networkPrincipal component analysisMice TransgenicBiologyTransfectionTranscriptomeCohort Studies03 medical and health sciencesMice0302 clinical medicineMathematical modelmicroRNAmedicineAnimalsHumansGene Regulatory NetworksCTNNB1Genebeta CateninHepatologySequence Analysis RNALiver NeoplasmsGene regulatory networkRNA-Binding ProteinsHGF/MET pathwayMicroRNAHep G2 CellsHCCSModels TheoreticalPrognosisPersonalized medicinedigestive system diseases030104 developmental biologymedicine.anatomical_structureCancer researchSMARCA4biology.protein030211 gastroenterology & hepatologyTranscriptome
researchProduct

Copper/MYC/CTR1 interplay: A dangerous relationship in hepatocellular carcinoma

2018

Free serum copper correlates with tumor incidence and progression of human cancers, including hepatocellular carcinoma (HCC). Copper extracellular uptake is provided by the transporter CTR1, whose expression is regulated to avoid excessive intracellular copper entry. Inadequate copper serum concentration is involved in the pathogenesis of Non Alcoholic Fatty Liver Disease (NAFLD), which is becoming a major cause of liver damage progression and HCC incidence. Finally, MYC is over-expressed in most of HCCs and is a critical regulator of cellular growth, tumor invasion and metastasis. The purpose of our study was to understand if higher serum copper concentrations might be involved in the prog…

0301 basic medicineCirrhosisCopper; CTR1; Hepatocellular carcinoma; MYC; Non alcoholic fatty liver disease; OncologyMYCMetastasis03 medical and health sciencesmedicineOncogeneCell growthChemistryFatty liverCTR1hepatocellular carcinomaHCCSmedicine.diseasedigestive system diseases3. Good health030104 developmental biologyOncologyHepatocellular carcinomacopperCancer researchCTR1; MYC; copper; hepatocellular carcinoma; non alcoholic fatty liver diseaseLiver cancerResearch Papernon alcoholic fatty liver disease
researchProduct

Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer

2016

Background & Aims Many different types of cancer cells have chromosome instability. The hippo pathway leads to phosphorylation of the transcriptional activator yes-associated protein 1 (YAP1, YAP), which regulates proliferation and has been associated with the development of liver cancer. We investigated the effects of hippo signaling via YAP on chromosome stability and hepatocarcinogenesis in humans and mice. Methods We analyzed transcriptome data from 242 patients with hepatocellular carcinoma (HCC) to search for gene signatures associated with chromosomal instability (CIN); we investigated associations with overall survival time and cancer recurrence using Kaplan–Meier curves. We analyze…

0301 basic medicineTime FactorsMuscle ProteinsKaplan-Meier Estimatemedicine.disease_causeChromosome instabilityYAP1Liver NeoplasmsGastroenterologyTEA Domain Transcription FactorsHep G2 CellsPrognosisDNA-Binding ProteinsGene Expression Regulation NeoplasticPhenotypeHippo signalingRNA InterferenceSignal TransductionCarcinoma HepatocellularPorphyrinsAntineoplastic AgentsMice TransgenicBiologyTransfection03 medical and health sciencesChromosomal InstabilitymedicineAnimalsHumansGene silencingGenetic Predisposition to DiseaseAdaptor Proteins Signal TransducingHippo signaling pathwayHepatologyGene Expression ProfilingForkhead Box Protein M1VerteporfinYAP-Signaling ProteinsHCCSPhosphoproteinsThiostreptonMolecular biologyMice Inbred C57BLDisease Models Animal030104 developmental biologyTissue Array AnalysisFOXM1Cancer researchTranscriptomeCarcinogenesisTranscription FactorsGastroenterology
researchProduct

Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients

2018

To retrospectively analyze the evolution of indeterminate hepatocellular nodules in cirrhotic patients on serial Gd-EOB-DPTA-enhanced MRI, and to identify predictors of HCC development. This IRB approved study included 33 cirrhotic patients with 69 indeterminate hepatocellular nodules (mean diameter 1.1 cm) at baseline Gd-EOB-DPTA-enhanced MRI and a Gd-EOB-DPTA-enhanced-MRI follow-up of at least 2 years. Two radiologists evaluated size and signal intensity of each nodule at baseline and follow-up. Age, cirrhosis etiology, and HCC history were recorded. Data were compared between nodules that became HCCs at follow-up (HCC) and those that did not (no-HCC). On follow-up, 5/69 nodules became HC…

AdultGadolinium DTPALiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularContrast MediaCirrhosis; Gd-EOB-DTPA; HCC; Indeterminate hepatocellular nodule; Liver MRIGastroenterology030218 nuclear medicine & medical imagingLiver MRI03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingHCCneoplasmsNeuroradiologyAgedRetrospective StudiesAged 80 and overCirrhosimedicine.diagnostic_testbusiness.industryLiver NeoplasmsIndeterminate hepatocellular noduleNodule (medicine)Magnetic resonance imagingGeneral MedicineHCCSMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesGd-EOB-DTPA030220 oncology & carcinogenesisPredictive value of testsEtiologyFemalemedicine.symptomIndeterminatebusiness
researchProduct

Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma

2011

The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical ana…

AdultLiver CirrhosisMaleMAPK/ERK pathwayCarcinoma HepatocellularSettore MED/09 - Medicina InternaSurvivinCell Cycle ProteinsPhosphatidylethanolamine Binding ProteinSettore MED/08 - Anatomia PatologicaBiologymedicine.disease_causeBiochemistryInhibitor of Apoptosis ProteinsSurvivinGeneticsmedicineHumansRNA MessengerHepatocellular carcinomaYY1RKIPMolecular BiologyTranscription factorYY1 Transcription FactorAgedAged 80 and overSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 Raf-1 Kinase Inhibitor Protein Yin Yang 1-associated proteinKinaseYY1Liver NeoplasmsNuclear ProteinsMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticLiverHepatocellular carcinomaembryonic structuresSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineFemaleSettore SECS-S/01 - StatisticaCarcinogenesisTranscription FactorsBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Hepatocellular carcinoma in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout.

2011

OBJECTIVES: Our aim was to compare retrospectively hepatic venous and delayed phase images for the detection of tumour washout during multiphasic multidetector row CT (MDCT) of the liver in patients with hepatocellular carcinoma (HCC). METHODS: 30 cirrhotic patients underwent multiphasic MDCT in the 90 days before liver transplantation. MDCT was performed before contrast medium administration and during hepatic arterial hepatic venous and delayed phases, images were obtained at 12, 55 and 120 s after trigger threshold. Two radiologists qualitatively evaluated images for lesion attenuation. Tumour washout was evaluated subjectively and objectively. Tumour-to-liver contrast (TLC) was measured…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationLesionmedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesFull Paperbusiness.industryLiver NeoplasmsLiver CT HCCWashoutVenous phaseGeneral MedicineDelayed phaseMiddle AgedHCCSmedicine.diseasedigestive system diseasesLiver TransplantationContrast mediumHepatocellular carcinomaFemaleRadiologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray Computedbusiness
researchProduct

Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis

2021

Development of primary liver cancer is a multistage process. Detailed understanding of sequential epigenetic alterations is largely missing. Here, we performed Infinium Human Methylation 450k BeadChips and RNA-Seq analyses for genome-wide methylome and transcriptome profiling of cirrhotic liver (n = 7), low- (n = 4) and high-grade (n = 9) dysplastic lesions, and early (n = 5) and progressed (n = 3) hepatocellular carcinomas (HCC) synchronously detected in 8 patients with HCC with chronic hepatitis B infection. Integrative analyses of epigenetically driven molecular changes were identified and validated in 2 independent cohorts comprising 887 HCCs. Mitochondrial DNA sequencing was further em…

AdultMaleMitochondrial DNACarcinoma HepatocellularCirrhosisMolecular biologyCarcinogenesisBiologyEpigenesis GeneticHepatitis B ChronicmedicineHumansEpigeneticsAgedHepatologyGene Expression ProfilingLiver NeoplasmsDNA NeoplasmGeneral MedicineMethylationDNA MethylationMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticOncologyApoptosisDNA methylationCancer researchEpigeneticsCalmodulin-Binding ProteinsFemaleLiver cancerLiver cancerResearch ArticleJCI Insight
researchProduct

MicroRNAs as Novel Targets in Liver Cancer: Facing the Clinical Challenge

2014

Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide with a rising incidence in the western world. HCCs are characterized by a phenotypic and molecular heterogeneity that limits therapeutic progress. MicroRNAs play a major role for the pathogenesis and progression of liver cancer. As an essential part of the RNA interference machinery, microRNAs contribute to the regulation of many pro-oncogenic processes in HCC, including proliferation, migration, and survival. Therefore, these epigenetically active small molecules advanced to attractive targets for both diagnosis and therapy of liver cancer. Here, we will try to delineate the role of microRNAs during liver de…

Alcoholic liver diseasePathologymedicine.medical_specialtybusiness.industryDiseaseHCCSmedicine.diseasedigestive system diseasesRNA interferenceHepatocellular carcinomamicroRNAmedicineCancer researchStem cellLiver cancerbusiness
researchProduct

Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma

2021

Simple Summary Individual patients with liver cancer have a highly variable clinical course. Hence, there is an urgent need to identify new prognostic markers to determine prognosis and select specific therapies. Expression of two key enzymes in pyrimidine synthesis was analyzed in a large, well-characterized cohort of patients with liver cancer. Dysregulated expression of these enzymes was associated with shorter survival of the patients. A combined score of both markers was found to be a statistically independent prognostic marker. Abstract Patients with hepatocellular carcinoma (HCC) have a highly variable clinical course. Therefore, there is an urgent need to identify new prognostic mar…

Cancer ResearchpyrimidineCADlcsh:RC254-282Article03 medical and health sciences0302 clinical medicinecps1medicineHCCchemistry.chemical_classificationTissue microarraybusiness.industryCancerhepatocellular carcinomaHCCSmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensurea cycle dysregulationEnzymeDihydroorotasechemistryOncology030220 oncology & carcinogenesisHepatocellular carcinomaPyrimidine metabolismKey (cryptography)Cancer researchImmunohistochemistryBiomarker (medicine)biomarkercad030211 gastroenterology & hepatologyprognosisbusinessCancers
researchProduct

Cyclooxygenases in hepatocellular carcinoma

2006

Many epidemiological studies demonstrate that treatment with non-steroidal anti-inflammatory drugs (NSAIDs) reduce the incidence and mortality of certain malignancies, especially gastrointestinal cancer. The cyclooxygenase (COX) enzymes are well-known targets of NSAIDs. However, conventional NSAIDs non-selectively inhibit both the constitutive form COX-1, and the inducible form COX-2. Recent evidence indicates that COX-2 is an important molecular target for anticancer therapies. Its expression is undetectable in most normal tissues, and is highly induced by pro-inflammatory cytokines, mitogens, tumor promoters and growth factors. It is now well-established that COX-2 is chronically overexpr…

Carcinoma HepatocellularAngiogenesisBiologymedicine.disease_causeModels BiologicalGene Expression Regulation EnzymologicIn vivomedicineHumansNeoplasm InvasivenessGastrointestinal cancerEnzyme InhibitorsCell growthAnti-Inflammatory Agents Non-SteroidalLiver NeoplasmsGastroenterologyGeneral MedicineHCCSmedicine.diseasedigestive system diseasesGene Expression Regulation NeoplasticEditorialModels ChemicalCyclooxygenase 2Hepatocellular carcinomaImmunologyCyclooxygenase 1Cancer researchCarcinogenesisLiver cancer
researchProduct